Please provide your email address to receive an email when new articles are posted on . Glaukos submitted a new drug application to the FDA for Epioxa, an epithelium-on corneal cross-linking iLink ...
Please provide your email address to receive an email when new articles are posted on . Patient registries have shown that PK rates for keratoconus decreased after the introduction of cross-linking.
On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...
SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase ...
Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...
Glaukos (GKOS) announced the submission of its New Drug Application NDA to the U.S. Food and Drug Administration FDA or Epioxa or Epi-on, its next-generation corneal cross-linking iLink therapy for ...
SEATTLE — Keeping our vision strong is important throughout life. Conditions like keratoconus, though, can cause vision to decline. “The cornea is important to be clear,” said Dr. Luke Barker of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback